About Us
Guangzhou Anjie Biomedical Technology Co., Ltd.
As the only high-tech enterprise within the Nanshan Research Institute system dedicated exclusively to cell research, we have deeply integrated scientific research resources to focus on the application and development of immune cells and stem cells since our establishment and commencement of operations in 2017. The company has built an efficient end-to-end cell therapy product management system, covering the entire process from R&D to manufacturing to clinical application.
Guided by the mission of “Continuously developing high-quality, innovative cell therapy products to precisely meet humanity’s pursuit of health and longevity,” and the vision of “Becoming the leading cell therapy enterprise in the Asia-Pacific region and joining the first tier of the global cell therapy industry,” we are steadily advancing technological innovation and industrial implementation. With science and technology as our driving force, we are committed to safeguarding human health and longevity.
Focusing on Core Fields, Addressing Unmet Clinical Needs
We focus on the core field of tumor immunotherapy, dedicated to advancing the R&D and industrialization of original immune cell therapies, tumor neoantigen products, and therapeutic cancer vaccines. Our aim is to tackle the toughest challenges in cancer treatment and fill critical gaps in clinical demand.
Pioneering Global Technologies, Driving Industry Advancement
Our independently developed PD-1 gene knockout CAR-T cells targeting MUC1 represent a world-first achievement. This breakthrough overcomes the limitations of traditional CAR-T technology, providing a novel solution for precision oncology and driving the next generation of cell therapy innovations.
Recognized by Authorities, Demonstrating Strong Capabilities
-
International Recognition: Results from our CAR-T cell clinical trials were rigorously selected for oral presentation at the European Society for Medical Oncology (ESMO) Annual Congress, earning high recognition from global oncology experts.
-
Government-Endorsed Platforms: We have successfully established the Guangdong Provincial Key Laboratory for Tumor Immunotherapy, the Key Laboratory for Monitoring Adverse Reactions to CAR-T Cell Therapy, and the Guangdong Provincial Engineering Technology Research Center for Precision Treatment of Esophageal Cancer, securing strong governmental support and access to premium research resources.
Global Collaboration, Accelerating Innovation
Through partnerships with top-tier institutions such as Harvard Medical School and the University of Technology Sydney, as well as renowned universities in China including Sun Yat-sen University and Guangzhou Medical University, we have built a collaborative ecosystem integrating industry, academia, research and clinical medicine. By uniting global expertise, we accelerate innovation and breakthroughs in the field of cell therapy.
.png)
.png)
.png)
.png)